SWOG clinical trial number
SWOG-8216/38

Comparison of BCG Immunotherapy and Adriamycin for Superficial Bladder Cancer

Closed
Phase
III
Published
Abbreviated Title
BCG - Bladder
Activated
12/01/1982
Closed
01/15/1987

Research committees

Genitourinary Cancer

Treatment

Adriamycin® BCG

Publication Information Expand/Collapse

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

1996

Local toxicity patterns associated with intravesical bacillus calmette-guerin. A Southwest Oncology Group study.

DL Berry;BA Blumenstein;DL Magyary;DL Lamm;ED Crawford International Journal of Urology 3:98-100

1991

A randomized clinical trial of intravesical doxorubicin immunotherapy with Bacille Calmette-Guerin for transitional carcinoma of the bladder. A Southwest Oncology Group study.

DL Lamm;BA Blumenstein;ED Crawford;JE Montie;P Scardino;HB Grossman;TH Stanisic;JA Smith;J Sullivan;MF Sarosdy;JD Crissman;C Coltman, Jr NEJM 325:1205-1209

1990

Effect of colony-forming unit dose of connaught BCG on outcome to immunotherapy in superficial bladder cancer: A Southwest Oncology Group study.

B Blumenstein;D Lamm;MAS Jewett;G Humphries;L Boux;J Montie;P Scardino;H Grossman;D Crawford;JA Smith;T Stanisic Journal of Urology 143(4):340A

Fatal sepsis following intravesical bacillus calmette-guerin administrations for bladder cancer.

WH Rawls;DL Lamm;BA Lowe;ED Crawford;MF Sarosdy;JE Montie;HB Grossman;PT Scardino Urology 144:1328-1330

1989

BCG versus adriamycin intravesical therapy for in situ and papillary transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group study

DL Lamm;J Crissman;ED Crawford;B Blumenstein;JE Montie;PT Scardino;HB Grossman;T Stanisic;JA Smith;M Sarosdy ASCO 8:130(504)

1986

A trial of bacillus calmette-guerin versus adriamycin in superficial bladder cancer: A South-west Oncology Group study.

K Mori;DL Lamm;ED Crawford Urology Internationalis 41(4):254-259

1985

BCG versus adriamycin in bladder cancer: A Southwest Oncology Group study.

DL Lamm;ED Crawford ASCO :#C-424

BCG versus adriamycin in the treatment of transitional cell carcinoma in-situ: A Southwest Oncology Group study.

DL Lamm;ED Crawford Proc AUA 133:184A (#283)

Intravesical adriamycin for recurrent superficial bladder cancer: A Southwest Oncology Group study.

ED Crawford;DL Lamm;JE Montie;PT Scardino;HB Grossman;T Stanisic;JA Smith;JW Sullivan Proc AUA 133:213A (#397)

BCG versus adriamycin in bladder cancer: A Southwest Oncology Group study.

DL Lamm;ED Crawford Inter-American Society for Chemotherapy, p. 49, #E7

1984

Southwest Oncology Group experience with randomized protocols for bladder cancer.

JA Smith Jr;ED Crawford In: Controlled Clinical Trials in Urologic Oncology . L Denis, GP Murphy, GR Prout Jr, F Schroder, eds. New York: Raven Press 249-254

Other Clinical Trials

SWOG Clinical Trial Number
S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.

Research Committee(s)
Genitourinary Cancer
Activated
04/19/2019
Accrual
3%
Open
Phase
III
SWOG Clinical Trial Number
S1802
SWOG Clinical Trial Number
CTSU/EA8153